The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.

Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.

Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.

Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.

The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.

New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.